← Back to screener

Stoke Therapeutics, Inc. STOK

Rank #2357 · Nasdaq · $1.6B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
22.2
P/E
-18.4
P/B
10.26
ROE
-55.8%
Op. Margin
-277.3%
Debt Ratio
27%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -18.4x, P/B 10.26x. Ranks in the top 80% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -55.8%. Ranks in the top 91% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 27%. Ranks in the top 16% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 316.3% year over year. Ranks in the top 1% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2019–$-0.0B$-0.0B$-0.0B–-191
2020–$-0.0B$-0.0B$0.1B–4
2021–$-0.1B$-0.1B$0.2B–5
2022$0.0B$-0.1B$-0.1B$0.3B-693.87
2023$0.0B$-0.1B$-0.1B$0.2B-841.233
2024$0.0B$-0.1B$-0.1B$0.2B-1307.237
2025$0.0B$-0.1B$-0.1B$0.2B-277.327

← See the full screener